|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6500 - 0.6500|
|52 Week Range||0.5100 - 0.9400|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||29.55|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abbott Laboratories announced Monday that it had received critical European approval for the newest version of its FreeStyle Libre continuous glucose monitoring system; ABT stock rose.
DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of its paper, "Long-term Cost-effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring in Patients with Type 1 Diabetes in the UK" in Diabetes Care.
Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Diabetes Research